Drug Type Small molecule drug |
Synonyms Herbuvir, Holybuvir, 和乐布韦 + [3] |
Target |
Action inhibitors |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (12 May 2023), |
RegulationSpecial Review Project (China), Priority Review (China) |
Molecular FormulaC28H33FN3O9P |
InChIKeyAGNGNQMSDCXIGL-HDXCYPIWSA-N |
CAS Registry2236586-64-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C, Chronic | China | 12 May 2023 |
Phase 3 | 326 | (szfrepguqc) = tbfgmvhjyf lcnzwhoseu (gzchphgafy, 96.5% - 99.5) | Positive | 01 Nov 2023 | |||
Phase 2 | 124 | (jahircgnzu) = jqnmvufaam obsljigqxg (qqpztkcifd ) | Positive | 26 Jan 2022 | |||
(jahircgnzu) = caxhcgkofc obsljigqxg (qqpztkcifd ) | |||||||
Phase 3 | 327 | yzosbaywkz(tblcwutbxn) = rvpzjhpxcz ziyydxvqxv (pelixiuwzy, 96.5% - 99.5%) | Positive | 23 Jun 2021 | |||
Phase 2 | 124 | kjzcxpjwws(xkfktxtfyb) = cmlyoyapvd xjbppmcdmc (wgmjxhveqd ) View more | Positive | 27 Aug 2020 | |||
kjzcxpjwws(xkfktxtfyb) = rviyfjvjfe xjbppmcdmc (wgmjxhveqd ) View more |